Core Viewpoint - Morgan Stanley anticipates that WuXi Biologics' stock price will rise in the next 45 days, with a probability estimated between 70% to 80% [1] Group 1: Financial Performance and Projections - The company previously issued an earnings upgrade, with management indicating accelerated growth for the fiscal year 2026 [1] - The number of integration projects for 2025 is expected to increase by 16%, reflecting strong momentum in research services [1] - The strong momentum in research services is expected to generate revenue related to intellectual property (IP), further enhancing profitability [1] Group 2: Strategic Partnerships and Growth Indicators - Recently, the company has entered into licensing agreements with Vertex and Zai Lab [1] - WuXi Biologics anticipates strong growth in its manufacturing segment, with several blockbuster drugs expected [1] - The company completed 28 process performance qualifications (PPQ) in 2025, representing a year-on-year growth of 75%, which is viewed as a leading indicator for future commercialization contracts [1] Group 3: Earnings Forecast and Target Price Adjustment - Based on accelerated revenue growth and margin expansion, Morgan Stanley has raised its earnings forecasts for 2026 to 2030 by 4% to 10% [1] - The target price has been adjusted from HKD 45 to HKD 50, while maintaining an "Overweight" rating [1]

Core Viewpoint - Morgan Stanley believes that China National Airlines (00753) has a 70% to 80% chance of stock price increase in the next 60 days, with a target price set at HKD 8.11 and a rating of "Overweight" [1] Group 1: Company Performance - The third-quarter earnings performance of China National Airlines was disappointing, leading to a decline in stock price [1] - The parent company has proposed a capital injection, which contributed to the stock price drop [1] Group 2: Market Outlook - Morgan Stanley maintains a constructive view on the upward cycle of domestic airlines, believing that the recent stock price adjustment presents an ideal buying opportunity for the market [1] - The firm anticipates that improving business travel demand, along with higher asset utilization rates among domestic airlines, will support their pricing power [1]

Core Viewpoint - Morgan Stanley predicts that China Resources Mixc Lifestyle (01209) has over an 80% chance of stock price increase within the next 30 days, citing recent adjustments have made the short-term valuation more attractive [2] Group 1: Stock Performance and Valuation - Morgan Stanley gives a "Buy" rating with a target price of HKD 42.49 [2] - The stock price has recently adjusted, leading to a more appealing short-term valuation [2] Group 2: Cash Flow and Dividend Outlook - Despite investor concerns regarding cash collection, Morgan Stanley notes that the current cash collection rates across all business segments have improved [2] - The management expects to achieve an operating cash flow to net profit ratio of approximately 1x for the year, supported by proactive collection measures [2] - The company is anticipated to maintain a 100% dividend payout ratio, providing a dividend yield of 5% to 6% from 2025 to 2027 due to ample cash reserves [2]

Core Viewpoint - Morgan Stanley's report predicts that Greentown Service's stock price will rise in the next 15 days, with a probability between 70% and 80%, and maintains an "Overweight" rating with a target price of HKD 5.18 [1] Financial Performance - Greentown Service's half-year performance is solid, with core profit increasing by 25% year-on-year on a comparable basis, making it one of the fastest-growing companies in the property management sector [1] - The strong profit margin expansion exceeded expectations, indicating robust execution under the new management team [1] Future Outlook - The report suggests that the performance enhances visibility for annual profit growth, which may lead to upward revisions in market forecasts [1] - The company is on track to expand with new contracts worth HKD 1.5 billion [1]